阿杜卡努马布:在批准两年后的展望
Astrid Torres1, Loida Camargo2, Norman López3
1Programa Neurología Clínica, Universidad del Sinú, Cartagena, Colombia.
Biomedica : revista del Instituto Nacional de Salud
|July 30, 2024
概括
阿杜卡努马布是一种阿尔茨海默病治疗方法,尽管在试验中有效性有限,但仍面临FDA批准. 本综述审查了其有争议的历史和未来对痴呆症护理的治疗影响.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 阿尔茨海默氏症是全球痴呆的主要原因,构成了重大的公共卫生挑战.
- 与心血管疾病死亡人数下降不同,与阿尔茨海默氏症相关的死亡人数正在上升,突出显示迫切需要有效的治疗方法.
- 目前阿尔茨海默氏症的治疗方法缺乏治愈方案,这使得治疗开发成为全球优先事项.
研究的目的:
- 审查Aducanumab的有争议的批准和临床表现,Aducanumab是一种针对β-粉样蛋白的单克隆抗体.
- 分析Aducanumab获得FDA批准及其对阿尔茨海默病治疗策略的影响.
- 根据Aducanumab的试验结果,讨论阿尔茨海默病治疗方法的未来前景.
主要方法:
- 对阿杜卡努马布的开发,临床试验和监管历史的文献综述.
- 对Aducanumab的疗效和安全性进行第三期试验数据的分析.
- 对阿杜卡努马布的接受性进行专家意见和公共卫生观点的审查.
主要成果:
- 抗胺β抗体阿杜卡努马布于2021年6月获得FDA批准.
- 第三阶段临床试验表明,阿杜卡努马布没有达到初级疗效终点.
- 药物的批准被其临床益处的重大争议所标志.
结论:
- 阿杜卡努马布的批准凸显了阿尔茨海默氏症药物开发和监管过程中的挑战.
- 药物的有效性有限,这引发了关于粉样β假设和未来治疗点的问题.
- 需要进一步的研究来开发更有效的阿尔茨海默病治疗方法.
更多相关视频
06:40Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
Published on: January 25, 2018
6.7K
09:49Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021
3.4K
相关概念视频
01:19Pharmacovigilance
805
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
805
01:11Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124